Pfizer's and BioNTech's vaccine candidate has been crushing it in clinical trials. Their latest data, revealed Wednesday morning, shows that the candidate is 95 percent effective and has consistent results across "age, gender, race and ethnicity demographics." On top of that, they've reported no serious safety concerns. "Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group." The results should be celebrated. And they have been, by people not interested in politics. But…
All news text, graphics, videos and multimedia content remain the copyrights of the credited original article publisher, in this case - Latest Articles
Amnon Free Press is an American conservative news aggregator and publisher with a mission to publish the right news for the right American.
Contact Information: admin (at) amnonfreepress dot com